March 2023

Contents

Editorial

• HTB March 2023 (10 March 2023)

• Supporting Ukraine

Conference reports

• 30th Conference on Retroviruses and OIs (CROI 2023): first reports

• CROI 2023: Pipeline HIV drugs and formulations for treatment and PrEP

• CROI 2023: Six-monthly ART – lenacapavir + dual bNAbs maintains undetectable viral load for 26 weeks after single doses

• CROI 2023: Other lenacapavir studies – experienced and naive updates, the dosing window, HIV-2 and PrEP

• CROI 2023: Similar PK profile for thigh vs gluteal CAB/RPV-LA injections: accidental intravenous injection

• CROI 2023: Efficacy of N6LS monotherapy correlated with baseline factors

• CROI 2023: CAB/RPV-LA levels are not reduced after switching from efavirenz

• CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study

• CROI 2023: Point-of-care testing for mothers and infants: results from the LIFE study

• CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young adults

• CROI 2023: Single dose doxycycline as PEP for STIs (doxy-PEP): five studies

• CROI 2023: Severe mpox outcomes with a low CD4 count and detectable viral load: a new AIDS-defining condition?

Cure-related research

• The Düsseldorf patient HIV cure case published in Nature Medicine

Treatment advocacy

• UK-CAB online training: webinar programme every two weeks

• New community platform on HIV and mental health: in 10 EU languages

PDFs

• HTB: no. 3 (March 2023) PDF download